Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers

Completed

• Conditions: Corona Virus Infection; COVID
• Interventions: Biological: Specific anti-SARS-CoV-2 antibodies

• Registration Number: NCT04424017
• Lead Sponsor: Egyptian Center for Research and Regenerative Medicine

Brief Summary

The medical and paramedical staff of the front-line services are potentially exposed to SARS-CoV-2. Therefore, despite the application of standard protective measures, it is possible that a certain number of these personnel have already contracted SARS-CoV-2, including in its asymptomatic form. Serological testing in this context would be useful for deploying immune healthcare workers as to limit the risk of viral infection and transmission. Therefore, it is of utmost importance to prove that the serological response entails the production of neutralizing antibodies.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-06-07
• Study First Submitted: 2020-06-08
• Study First Submitted QC: 2020-06-08
• Study First Posted: 2020-06-09
• Primary Completion: 2020-10-30
• Study Completion: 2020-10-30
• Status Verified: 2021-03
• Last Update Submitted: 2021-03-07
• Last Update Posted: 2021-03-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1546

Inclusion Criteria

• Not previously diagnosed with COVID-19 except for convalescents
• Not currently symptomatic with fever or respiratory symptoms (cough, dyspnea)

Exclusion Criteria

• Patients with fever or respiratory symptoms (cough, dyspnea)
• Refusal to give informed consent, or contraindication to venipuncture.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Healthcare workers (HCWs)	Specific anti-SARS-CoV-2 antibodies	-
Convalescents	Specific anti-SARS-CoV-2 antibodies	-
Healthy blood donors and healthy subjects in blood bank	Specific anti-SARS-CoV-2 antibodies	-

Primary Outcome Measures

Name	Time	Method
Describe the serological status of individuals in the study by presence of specific anti-SARS-CoV-2 antibodies	3 Months

Trial Locations

Locations (2)

ECRRM; 🇪🇬 Cairo, Egypt

Faculty of Medicine, Cairo University; 🇪🇬 Cairo, Egypt